Mavrilimumab

Mavrilimumab is a human monoclonal antibody that is designed for the treatment of rheumatoid arthritis. It is an immunoglobulin G4, anti-granulocyte macrophage colony-stimulating factor (GM-CSF) receptor α monoclonal antibody. Mavrilimumab was developed by MedImmune, a subsidiary of AstraZeneca.

Mechanism of Action

Mavrilimumab works by binding to the alpha chain of the GM-CSF receptor, inhibiting GM-CSF signaling. GM-CSF is a cytokine that plays a crucial role in inflammation and autoimmunity, including the pathogenesis of rheumatoid arthritis.

Clinical Trials

Mavrilimumab has undergone Phase IIb clinical trials for rheumatoid arthritis. The results showed that the drug was well-tolerated and led to improvements in disease activity. It is currently undergoing Phase III trials.

COVID-19 Treatment

In 2020, mavrilimumab was investigated as a potential treatment for COVID-19. Preliminary results from a small, single-center, open-label study in Italy suggested that mavrilimumab may reduce the risk of respiratory failure and death in patients with severe COVID-19 pneumonia.

See Also

• List of investigational drugs
• Monoclonal antibodies
• Rheumatoid arthritis

Mavrilimumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski